FDA Approves Expanded Use of Vutrisiran for Cardiomyopathy in Transthyretin Amyloidosis: A Landmark Advancement in Treatment Options
FDA Approves AMVUTTRA® (vutrisiran) for ATTR Amyloidosis with Cardiomyopathy, Offering New Hope for U.S. Patients This RNAi therapeutic promises to reduce cardiovascular death, hospitalizations, and urgent heart failure visits for Americans battling ATTR-CM. Published: March 24, 2025 The U.S. Food and Drug Administration (FDA) has expanded its approval for AMVUTTRA® (vutrisiran), now including the treatment … Read more